receptor antagonistic activity. However, 19 showed only weak gastrointestinal prokinetic activity after oral administration. Several ester prodrugs (44-62) of 19 were tested for pharmacological activities as well as physicochemical and metabolic stability; the butyl ester (46) was consequently selected as a promising gastrointestinal prokinetic agent with reduced side effects.
合成了各自具有环
氨基链烷
羧酸侧链的新型苯甲酰胺衍
生物(19-24、32a-c,43d-f),并评估了它们的胃肠道动力学和
多巴胺D2受体拮抗剂活性。4-[(4-
氨基-5-
氯-2-
甲氧基苯甲酰基)
氨基] -1-
哌啶乙酸(19)通过对有意识的犬静脉内给药,表现出最强的胃肠和结肠运动活性,并且还表现出降低的活性。
多巴胺D2受体的拮抗活性。然而,有19只在口服后显示出较弱的胃肠道运动活性。测试了19种
酯类前药(44-62)的药理活性以及理化和代谢稳定性;因此,选择了丁基酯(46)作为有希望的副作用少的胃肠道促动力剂。